| abstract |
The invention relates to novel 2-substituted Estra-1,3,5 (10) -triene-17-ones of the general formula I wherein R 2 is a saturated or unsaturated C 1 -C 8 -alkyl group, a C 1 -C 5 -alkyloxy group, an aralkyl or alkylaryl radical, a radical -OC n F m H o , where n = 1, 2, 3, 4, 5 or 6, m ≧ 1 and m + o = 2n + 1, or a group CH 2 XY in which X is an oxygen atom and Y is an alkyl radical having 1 to 4 carbon atoms, and a halogen atom or a nitrile group, R 13 is a hydrogen atom or a methyl group, R 16 is a hydrogen or a fluorine atom, Z is an oxygen or a sulfur atom, R 3 and R 5 are each independently an α- or β-position hydrogen atom, R 4 and R 6 are each independently an alpha or beta hydrogen, a C 1 -C 5 alkyl, a C 1 -C 5 alkyloxy, a C 1 -C 5 acyl or a hydroxy group, or an aralkyl or alkylaryl radical, R 3 and R 4 together represent an oxygen atom, R 5 and R 6 together represent an oxygen atom, R 7 and R 8 each represent a hydrogen atom or together represent a CH 2 group, and their pharmaceutically acceptable salts, their preparation and use as medicaments for the prophylaxis and therapy of estrogen-dependent diseases which can be influenced by inhibition of 17β-hydroxysteroid dehydrogenase type 1 |